2020
Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer
Shuch B, Li S, Risch H, Bindra RS, McGillivray PD, Gerstein M. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. Cancer 2020, 126: 3657-3666. PMID: 32413184, PMCID: PMC10316675, DOI: 10.1002/cncr.32914.Peer-Reviewed Original ResearchConceptsFumarate hydrataseExome Aggregation ConsortiumAllele frequenciesFH geneGenome ProjectDifferent world populationsFH alterationsHereditary leiomyomatosisKidney cancer riskCancer penetranceMissense alterationsGenesOverall allele frequencyRare variantsLow penetranceRenal cancerExACKidney cancerCancer riskPenetranceGermline mutationsLethal formWorld populationCancer syndromesAlterations
2019
DNMT3A co-mutation in an IDH1-mutant glioblastoma
Fomchenko EI, Erson-Omay EZ, Zhao A, Bindra RS, Huttner A, Fulbright RK, Moliterno J. DNMT3A co-mutation in an IDH1-mutant glioblastoma. Molecular Case Studies 2019, 5: a004119. PMID: 31371348, PMCID: PMC6672028, DOI: 10.1101/mcs.a004119.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorBrain NeoplasmsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3ADNA Modification MethylasesEpigenesis, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticGlioblastomaGliomaHumansIsocitrate DehydrogenaseMaleMutationMutation, MissensePromoter Regions, GeneticConceptsIDH1-mutant glioblastomaEpigenetic controlHistone modificationsTranscriptional regulationDNA methylationExpression profilesGlioblastoma biologySomatic mutationsDe novoMutationsMutant glioblastomasTumor landscapeMutational profileTargeted therapeutic approachesGlioblastomaImportant roleMethylationDNMT3ABiologyGliomagenesisMissenseRegulationNovoPrimary brain tumorsTherapeutic approachesDefining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis
JAIRAM V, KANN BH, PARK HS, MICCIO JA, BECKTA JM, YU JB, PRABHU RS, GAO SJ, MEHTA MP, CURRAN WJ, BINDRA RS, CONTESSA JN, PATEL KR. Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research 2019, 39: 2911-2918. PMID: 31177129, DOI: 10.21873/anticanres.13420.Peer-Reviewed Original ResearchConceptsIntermediate-risk groupInferior overall survivalOverall survivalAdjuvant therapyLow-grade gliomasTumor sizePrognostic featuresMultivariate analysisPre-operative tumor sizeNational Cancer Database AnalysisNational Cancer DatabaseLow-risk patientsCohort of patientsKaplan-Meier methodPoor prognostic featuresGross total resectionHigh-risk groupPatterns of careAdditional prognostic featuresRTOG 9802Clinical factorsTotal resectionCancer DatabaseRisk groupsClinical classificationRe: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452–8
Liang J, Beckta JM, Bindra RS. Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452–8. European Urology 2019, 76: e109-e110. PMID: 31080125, DOI: 10.1016/j.eururo.2019.04.041.Peer-Reviewed Original ResearchNanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma
Seo YE, Suh HW, Bahal R, Josowitz A, Zhang J, Song E, Cui J, Noorbakhsh S, Jackson C, Bu T, Piotrowski-Daspit A, Bindra R, Saltzman WM. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 2019, 201: 87-98. PMID: 30802686, PMCID: PMC6451656, DOI: 10.1016/j.biomaterials.2019.02.016.Peer-Reviewed Original ResearchConceptsEfficient intracellular deliveryDelivery systemPeptide nucleic acidNanoparticle productsNanoparticlesIntracellular deliveryConvection-enhanced deliveryDifferent delivery systemsNucleic acidsSignificant therapeutic efficacyMiR-21 suppressionTherapeutic efficacyLocal deliveryDeliverySystemic toxicityBlock copolymersDistinct advantagesPolyglycerolMiR-21
2018
Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors
Chen EM, Quijano AR, Seo YE, Jackson C, Josowitz AD, Noorbakhsh S, Merlettini A, Sundaram RK, Focarete ML, Jiang Z, Bindra RS, Saltzman WM. Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials 2018, 178: 193-203. PMID: 29936153, PMCID: PMC6082184, DOI: 10.1016/j.biomaterials.2018.06.024.Peer-Reviewed Original ResearchResidual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging
Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers A, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon K, Wen PY, Bindra RS, Woo J, Arnaout O, Gerstner ER, Zhang PJ, Rosen BR, Yang L, Huang RY, Kalpathy-Cramer J. Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging. Clinical Cancer Research 2018, 24: clincanres.2236.2017. PMID: 29167275, PMCID: PMC6051535, DOI: 10.1158/1078-0432.ccr-17-2236.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrainBrain NeoplasmsDatasets as TopicFemaleGliomaHumansImage Processing, Computer-AssistedIsocitrate DehydrogenaseMagnetic Resonance ImagingMaleMiddle AgedMutationNeoplasm GradingNeural Networks, ComputerPredictive Value of TestsPreoperative PeriodRetrospective StudiesYoung AdultConceptsResidual convolutional neural networkConvolutional neural networkNeural networkDeep learning techniquesTesting setNeural network modelMulti-institutional data setCancer Imaging ArchiveLearning techniquesTesting accuracyNetwork modelTraining setPrediction accuracyPreoperative radiographic dataClin Cancer ResData setsConventional MR imagingHospital of UniversityIsocitrate dehydrogenase (IDH) mutationPreoperative imagingLonger survivalWomen's HospitalGrade IINetworkTreatment decisionsYale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/s1470-2045(17)30916-6.Peer-Reviewed Case Reports and Technical Notes
2017
Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery
Chowdhary M, Okwan-Duodu D, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Zhong J, Chapman BV, Bindra RS, Contessa JN, Park HS, Yu JB, Decker RH, Olson JJ, Oyesiku NM, Abrams RA, Shu HG, Curran WJ, Crocker IR, Patel KR. Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. Journal Of Neuro-Oncology 2017, 136: 289-298. PMID: 29124649, PMCID: PMC5784434, DOI: 10.1007/s11060-017-2652-0.Peer-Reviewed Original ResearchConceptsSymptomatic radiation necrosisOverall survivalStereotactic radiosurgeryIntracranial efficacyRadiation necrosisKaplan-Meier methodLate radiation toxicitySignificant predictive factorsArteriovenous malformation patientsCumulative incidence modelsIntracranial outcomesBaseline characteristicsBlockade therapyBrain metastasesProspective trialABT groupConsecutive patientsMedian ageMeier methodPreclinical evidencePredictive factorsAVM cohortsRadiation toxicityPrognostic analysisMultivariate analysisPatterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas
Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB. Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy And Oncology 2017, 125: 258-265. PMID: 29054377, DOI: 10.1016/j.radonc.2017.09.027.Peer-Reviewed Original ResearchConceptsUse of CCRTConcurrent chemoradiotherapyPatterns of careAnaplastic gliomasOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingMultivariable logistic regression analysisConcurrent CRTNational Cancer DatabaseKaplan-Meier analysisLog-rank testLogistic regression analysisGrade III gliomasAdjusted hazardAdult patientsImproved survivalCancer DatabaseDesign cohortRadiotherapyPropensity scorePatientsGliomasChemoradiotherapyRegression modelingLocal DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas
King AR, Corso CD, Chen EM, Song E, Bongiorni P, Chen Z, Sundaram RK, Bindra RS, Saltzman WM. Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. Molecular Cancer Therapeutics 2017, 16: 1456-1469. PMID: 28566437, PMCID: PMC5545124, DOI: 10.1158/1535-7163.mct-16-0788.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasPoor blood-brain barrier penetrationLocal disease progressionBlood-brain barrier penetrationEffect of radiotherapyIntrinsic pontine gliomaTreatment of glioblastomaMol Cancer TherCranial radiationDosing schedulesMultimodal treatmentIntracranial gliomasDisease progressionExtracranial tumorsPontine gliomaAggressive phenotypeRadiotherapy approachesGliomasMinimal toxicityRadiotherapyGlioblastomaBarrier penetrationTreatmentRadiosensitizerChemotherapyBi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis‐Filho J, Powell SN. Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. The Journal Of Pathology 2017, 242: 165-177. PMID: 28299801, PMCID: PMC5516531, DOI: 10.1002/path.4890.Peer-Reviewed Original ResearchConceptsBreast cancerGermline BRCA1/BRCA2 mutationsBRCA1/BRCA2 mutationsPrecision medicine-based approachPrimary breast cancerTumour-specific DNA repair defectsSporadic breast cancerGermline genetic alterationsBi-allelic lossWhole-exome sequencingSpecific mutational signaturesComprehensive genetic assessmentBRCA2 mutationsLarge-scale state transitionsBi-allelic alterationsCancerGenetic alterationsDNA repair defectsMutational signaturesTherapyAlterationsRepair defectsGene expressionGenetic assessmentHR genes
2016
Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children
Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. JAMA Oncology 2016, 2: 1574-1581. PMID: 27491009, DOI: 10.1001/jamaoncol.2016.2547.Peer-Reviewed Original ResearchConceptsPostoperative radiotherapyOverall survivalMultivariable logistic regressionNational Cancer Data BaseLogistic regressionAdjuvant chemotherapy strategyLow facility volumeNational treatment patternsMultivariable Cox regressionLong-term morbidityYear of diagnosisDay of surgeryKaplan-Meier analysisNational database analysisPoor overall survivalLog-rank testYoung childrenAge 3Adjuvant chemotherapyRadiotherapy patternsRadiotherapy utilizationWorse survivalDistant metastasisMultivariable analysisTreatment patternsAdjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factors
2015
Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report.
van Dams R, Park HS, Alomari AK, Ricciardi AS, Rao H, McNamara J, DiLuna ML, Bindra RS. Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report. Journal Of Neurosurgery Pediatrics 2015, 17: 434-8. PMID: 26636250, DOI: 10.3171/2015.8.peds15313.Peer-Reviewed Original ResearchConceptsPartial brain radiation therapyRadiation therapyCase reportSarcoma brain metastasesEvidence of diseaseGross tumor resectionGross total resectionBrain metastasesInflammatory changesIntracranial metastasesSarcoma metastasisTumor resectionMetastasisTherapyResectionPatientsLimited marginReasonable approachReportDexamethasoneDiseaseGyBrainMonths
2005
Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells
Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy And Oncology 2005, 76: 168-176. PMID: 16026872, DOI: 10.1016/j.radonc.2005.06.025.Peer-Reviewed Original ResearchConceptsProstate cancer cellsCell cycle distributionCancer cellsP53 genotypeCycle distributionProtein expressionRNA expressionPoor clinical outcomeInduction of hypoxiaMalignant prostate cell linesAbility of hypoxiaRepair genesProstate cell linesHypoxia-induced apoptosisHR-associated genesDouble-strand break repair genesClinical outcomesDNA double-strand break repair genesProstate cancerGene expressionIntratumoral hypoxiaVEGF expressionBPH-1Tumor cellsObserved genetic instability
2004
Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells
Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. Molecular And Cellular Biology 2004, 24: 8504-8518. PMID: 15367671, PMCID: PMC516750, DOI: 10.1128/mcb.24.19.8504-8518.2004.Peer-Reviewed Original ResearchMeSH KeywordsCell CycleDNA RepairDNA-Binding ProteinsDown-RegulationFemaleGene Expression RegulationHumansHypoxiaHypoxia-Inducible Factor 1Hypoxia-Inducible Factor 1, alpha SubunitIronMaleNuclear ProteinsProstatic NeoplasmsRecombination, GeneticRNA, MessengerTranscription FactorsTranscription, GeneticUterine Cervical NeoplasmsConceptsHomologous recombinationExpression of RAD51RAD51 expressionGenetic instabilityCancer cellsCritical DNA repair pathwaysDNA damage responseMultiple cancer cell typesDNA repair pathwaysLevels of RAD51Homologous recombination pathwayGene promoter activityTranscriptional repressionCell cycle profileCancer cell typesDamage responseMammalian cellsHypoxia-inducible factorDNA repairProtein stabilityRepair pathwaysAberrant regulationPromoter activityRAD51Hypoxic cancer cells